GT Biopharma News | finanzen.ch

Kurse + Charts + Realtime	News + Analysen	Fundamental	Unternehmen	zugeh. Wertpapiere	Aktion
Kurs + Chart	Chart (gross)	News + Adhoc	Bilanz/GuV	Termine	Strukturierte Produkte	Portfolio
Times + Sales	Chartvergleich	Analysen	Schätzungen	Profil		Watchlist
Börsenplätze	Realtime Push	Kursziele	Dividende/GV
Historisch			Analysen

Kurse + Charts + Realtime

News + Analysen

Fundamental

Unternehmen

zugeh. Wertpapiere

Aktion

Kurs + Chart

Chart (gross)

News + Adhoc

Bilanz/GuV

Termine

Strukturierte Produkte

Portfolio

Times + Sales

Chartvergleich

Analysen

Schätzungen

Profil

Watchlist

Börsenplätze

Realtime Push

Kursziele

Dividende/GV

Historisch

Analysen

21.05.24	GT Biopharma Announces $3.2 Mln Direct Offering Of Shares; Stock Up (RTTNews)
28.03.22	GT Biopharma Reports Fourth Quarter and Full-Year 2021 Financial Results and Provides Corporate Update (PR Newswire)
21.03.22	GT Biopharma Presents TriKE® Nanobody Pipeline (GTB-5550) Preclinical Multiple Myeloma Proof-of-Concept Data at 2022 EBMT Annual Meeting (PR Newswire)
09.03.22	GT Biopharma Presented Preclinical Data Demonstrating Novel Mesothelin-Targeted TriKE® Driving Cytotoxicity Across All Stages of Non-Small Cell Lung Cancer at ESMO TAT 2022 (PR Newswire)
03.03.22	GT Biopharma to Participate In-Person at 34th Annual ROTH Conference, March 13-15, 2022 (PR Newswire)
24.02.22	GT Biopharma to Present Pre-Clinical Data at Upcoming Medical Conferences (PR Newswire)
18.02.22	GT Biopharma Appoints Manu Ohri as Chief Financial Officer (PR Newswire)
20.01.22	GT Biopharma to Present at B. Riley Securities' Virtual Oncology Conference (PR Newswire)
06.01.22	GT Biopharma Reports Granting of Inducement Awards Under Nasdaq Listing Rule 5635(c)(4) (PR Newswire)
08.12.21	GT Biopharma Demonstrates Novel B7-H3 Targeting Dual Camelid Nanobody BiKE and GTB-5550 Induce NK Cell Activation Against Broad Spectrum of Tumors at ESMO IO Congress 2021 (PR Newswire)
30.11.21	GT Biopharma Abstract on Novel B7-H3 Immune Checkpoint Targeting Broad Spectrum Solid and Hematologic Malignancies Accepted for Presentation at ESMO IO Congress 2021 (PR Newswire)
24.11.21	GT BioPharma to Host a Management Update Conference Call (PR Newswire)
10.11.21	GT BioPharma Reports Third Quarter 2021 Financial Results and Provides Corporate Update (PR Newswire)
08.11.21	GT Biopharma Announces Executive Leadership Transition to Implement Next Phase of Strategic Journey (PR Newswire)
20.09.21	GT BioPharma's Next Generation Camelid TriKE® Nanobody Platform Highlighted at ESMO Congress 2021 (PR Newswire)
15.09.21	GT Biopharma Announces Updated Positive Safety Data From Phase 1 GTB-3550 Monotherapy TriKE™ Trial an Investigational Immunotherapy for Refractory Cancers to be Presented at ESMO Congress 2021 (PR Newswire)
13.09.21	GT Biopharma Advances GTB-3650, a Second-Generation Tri-Specific Killer Engager -TriKE®, Into IND-Enabling Studies (PR Newswire)
09.09.21	GT Biopharma Announces Issuance of Two New Patents Covering TriKE® Platform Technologies (PR Newswire)
08.09.21	GT Biopharma to Present at Upcoming September Investor Conferences (PR Newswire)
22.10.19	GT Biopharma Announces Solid Tumor Targeting TriKe™ Kills (PR Newswire)
26.09.19	GT Biopharma Announces HIV Trike™ Data to be Published (PR Newswire)
26.09.19	GT Biopharma Announces HIV Trike™ Data to be Published (PR Newswire)
26.09.19	GT Biopharma Announces HIV Trike™ Data to be Published (PR Newswire)
30.08.18	GT Biopharma's Chairman and Chief Executive Officer Raymond W Urbanski, M.D., Ph.D Provides Insight Into the Impact of the Recent Affimed/Roche-Genetech Collaboration (PR Newswire)
29.08.18	GT Biopharma's Chairman and Chief Executive Officer Provides Insight Into the Impact of the Recent Affimed/Roche-Genetech Collaboration (PR Newswire)
24.08.18	GT Biopharma Announces the Appointment of David Cardino, CPA, MBA as Vice President of Finance (PR Newswire)
14.08.18	GT Biopharma Announces GTBP CEO, Dr. Raymond Urbanski, to Make Presentation at the 2018 Wedbush PacGrow Healthcare Conference (PR Newswire)
25.07.18	GT Biopharma Announces the Addition of Dr. John N. Bonfiglio to its Board of Directors (PR Newswire)
19.07.18	GT Biopharma Inc. Announces Agreement with a Major Pharmaceutical Company to Study its Drug Candidate OXS-1550 in Combination With a Multi-Billion Dollar Oncology Drug (PR Newswire)

Aktien Top/Flop

SMI
SPI
SLI
SMIM
DAX
ESTOXX
Dow Jones
S&P 500
NASDAQ 100
Nikkei 225

Geberit	545.60	2.17 %	K V
Sika	235.80	1.51 %	K V
CieFinRichemont	127.65	1.43 %	K V
Part Grp Hldg	1’299.50	1.33 %	K V
Holcim	91.86	1.15 %	K V
Roche Hldg G	254.50	-0.66 %	K V
Lonza Grp	525.00	-0.72 %	K V
Sonova Hldg	297.70	-1.03 %	K V
Alcon	77.12	-1.20 %	K V
Swiss Life Hldg	690.40	-4.69 %	K V

mehr

Portfolioname Watchlistname
Portfolio
Name
Typ
Valor / ISIN
Börse
Anzahl
Aktueller Kurs
Kurszeit
Kaufpreis
Kaufdatum
Kaufwert	CHF
	Hinzufügen Speichern

Nachrichten zu GT Biopharma Inc Registered Shs

Aktien Top/Flop

Meistgelesene Nachrichten